Pharmaceuticals Saudi Arabia

Saudi Arabia Allogeneic Cell Therapy Market Analysis, 2024–2034

Saudi Arabia Allogeneic Cell Therapy Market Industry Trends and Forecast to 2034: Segmented by (Cell Type, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Saudi Arabia · 2024–2034 · estimates

Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $18.2 Mn Estimated value
Estimate 2025 $23.0 Mn 1.6% of the global market
Projected 2034 $187.8 Mn 717.8% Adds $164.9 Mn over 9 forecast years
CAGR 2025–2034 26.3% Faster than 92% of 180 Pharmaceuticals markets here
Key players 5 Companies profiled
  • Saudi Arabia is 1.63% of the global market.
  • In Middle East, the largest is Saudi Arabia (this report) at $23.0 Mn.
  • Fastest growing: Saudi Arabia (this report) at 26.3% a year.
  • Saudi Arabia ranks 1st of 2 by size in Middle East.

Market size projection

Saudi Arabia

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$164.9 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Allogeneic Cell Therapy Market market size by year, Saudi Arabia
YearMarket sizeChange that yearSince 2025
2024 (estimate) $18.2 Mn — —
2025 (base) $23.0 Mn +$4.8 Mn —
2026 (forecast) $29.0 Mn +$6.0 Mn +26.3%
2027 (forecast) $36.6 Mn +$7.6 Mn +59.5%
2028 (forecast) $46.3 Mn +$9.6 Mn +101.5%
2029 (forecast) $58.4 Mn +$12.2 Mn +154.5%
2030 (forecast) $73.8 Mn +$15.4 Mn +221.4%
2031 (forecast) $93.2 Mn +$19.4 Mn +305.9%
2032 (forecast) $117.8 Mn +$24.5 Mn +412.7%
2033 (forecast) $148.7 Mn +$31.0 Mn +547.5%
2034 (forecast) $187.8 Mn +$39.1 Mn +717.8%

Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $1.41 Bn
  2. US $629.0 Mn
  3. North America $596.0 Mn
  4. APAC $329.0 Mn
  5. Europe $238.5 Mn
  6. China $102.7 Mn
  7. Canada $98.3 Mn
  8. Japan $80.4 Mn
  9. Germany $55.9 Mn
  10. Middle East $57.2 Mn
  11. Latin America $56.5 Mn
  12. France $39.7 Mn
  13. Italy $33.5 Mn
  14. UK $30.3 Mn
  15. Spain $30.2 Mn
  16. Brazil $30.7 Mn
  17. India $30.6 Mn
  18. Ecuador $28.9 Mn
  19. Mexico $22.7 Mn
  20. Saudi Arabia (this report) $23.0 Mn
  21. Australia $19.3 Mn
  22. Africa $18.9 Mn
  23. New Zealand $16.5 Mn
  24. Russia $13.1 Mn
  25. South Africa $8.3 Mn
  26. UAE $7.8 Mn
  27. Egypt $4.3 Mn
  28. Philippines $3.0 Mn
  29. Hong Kong $2.4 Mn
  30. Malaysia $2.0 Mn
  31. Thailand $1.7 Mn
  32. Singapore $1.6 Mn
  33. Kenya $1.1 Mn

The Saudi Arabia Allogeneic Cell Therapy Market Analysis Executive Summary

Allogeneic cell therapies use cells from healthy donors to make ready-to-use treatments that do not have to be made for each patient.

Key segments of the allogeneic Cell Therapy market include cell type (T Cells, NK Cells and Stem Cells) and indication (Oncology, Autoimmune and Regenerative Medicine).

Saudi Arabia Allogeneic Cell Therapy Market Dynamics

Market Growth Drivers

Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the allogeneic Cell Therapy market.

Opportunity

Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the allogeneic Cell Therapy market.

Market Restraints

Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the allogeneic Cell Therapy market. Payers are still working out how to pay for one-time cures.

Competitive Landscape for Allogeneic Cell Therapy Market in Saudi Arabia

The allogeneic Cell Therapy market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Allogeneic Cell Therapy Market in Saudi Arabia

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for allogeneic Cell Therapy. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Saudi Arabia.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Allogeneic Cell Therapy right now, from free public sources.

Latest research 103 papers since 2021 (worldwide)

  1. Antibody‒cell conjugates: A novel "off-the-shelf" modality bridging ADCs and CAR-T for cancer immunotherapy. Acta pharmaceutica Sinica. B, 2026
  2. Immune Evasion Strategies of Human Poxviruses: A Roadmap for Engineering Low-Immunogenic CAR-Based and iPSC-Derived Cell Products. Cells, 2026
  3. HLA-Engineered iPSC-Derived Mesenchymal Stromal Cells for the Treatment of Osteoarthritis in Mice. Cells, 2026
  4. Allogeneic Human Bone Marrow-Derived Mesenchymal Stem Cells Accelerate Diabetic Wound Healing via Inflammation Suppression and Angiogenesis Promotion: A Preclinical Study. The Kaohsiung journal of medical sciences, 2026
  5. Genetically engineered hypoimmunogenic iPSCs: Strategies and considerations for clinical applications. Regenerative therapy, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Allogeneic Cell Therapy in context

Saudi Arabia compared

  • Health spending per person: 1,825 US$ per person (2023). World: 1,317 US$ per person (2023). 2nd highest of the 9 countries we cover in Middle East.[1]
  • Doctors: 3.41 per 1,000 people (2023). World: 1.86 per 1,000 people (2022). Highest of the 9 countries we cover in Middle East.[2]
  • People aged 65 and over: 3.1% of people (2025). World: 10.4% of people (2025). 6th highest of the 9 countries we cover in Middle East.[3]

Questions, answered with public data

How much research is published on Allogeneic Cell Therapy?
PubMed lists 103 papers added since January 2021 that match this market, worldwide.[4]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 13 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 13 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 13 Nov 2026.

[4] PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.

Free data on this topic

Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Allogeneic Cell Therapy in Saudi Arabia? Our analysts can size it for your plan. Talk to us See the public data Health figures for every country, free. Open the Public Health Dashboard

From our blog

Patient Support Programmes: Helping Patients Stay on TreatmentWHO says only about half of patients in developed countries take long-term medicines as prescribed. Patient… Biologic Safety Testing: The Quiet Backbone of Drug MakingEvery vaccine, antibody and cell therapy must be tested for sterility, purity and viruses before it reaches… Cell-Based Immunotherapy: Promise and PriceThe first CAR-T cell therapy was approved in the US in August 2017. These living drugs can work when other…
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in Saudi Arabia

See all
Same topic, other categories

Related on cell and gene therapy and biologics and biosimilars

See the topic